Sysmex (OTCMKTS:SSMXY) Posts Earnings Results, Beats Expectations By $0.01 EPS

Sysmex (OTCMKTS:SSMXY) released its earnings results on Thursday. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01, reports. The business had revenue of $837.32 million during the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%.

Sysmex Stock Performance

SSMXY opened at $8.47 on Friday. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The firm has a market cap of $5.33 billion, a PE ratio of 16.94 and a beta of 1.14. The business has a fifty day simple moving average of $9.74 and a 200-day simple moving average of $11.39. Sysmex has a fifty-two week low of $8.15 and a fifty-two week high of $19.85.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.